Dosage Guidelines for Sildenafil Oral Solution

ODFs with their convenience, together with

Rights and permissions

Since its launch for the treatment of ED in 1998 in the market, there has been a well-established evidence base for its effectiveness and safety of sildenafil. It is the most efficacious drug, from a vascular perspective, among other PDE5-Is [Citation99]. This established efficacy of sildenafil in ED is irrespective of confounding factors including age, baseline severity, or etiology of ED [Citation100]. Although, sildenafil ODT is marketed at various strengths of 25, 50, sildenafil citrate 150 mg red pill and 100 mg, 50 mg is the recommended dose for most of the patients with directions to be approximately taken one hour before sexual activity. The dose can be titrated to a maximum of 100 mg or reduced to 25 mg considering individual patient’s needs, tolerability, and efficacy.

Does sildenafil interact with foods or drinks?

Headache and flushing are the most commonly reported side effects [Citation101]. Sildenafil is supplied in both solid film-coated tablet (FCT) and orodispersible tablet formulations. The sildenafil ODT and ODFs are made available through implementation of innovative manufacturing technologies [Citation8,Citation102]. It is also offered as chewable tablets and an orally soluble orodispersible film formulation [Citation82]. conducted a randomized clinical trial that reported bioequivalence of sildenafil ODT with or without water compared to marketed film-coated tablets. superior dosing accuracy and swift onset

• Patients should avoid heavy meals before taking sildenafil solution.
• Use caution if combining with other blood pressure medications.
• Regular medical check-ups are advised during treatment.

of action, have transpired in strong

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	100mg	120 + 6 Pills	149.50€ 142.38€	Buy
Viagra Generic	200mg	120 + 8 Pills	204.80€ 195.05€	Buy
Viagra Generic	200mg	360 + 10 Pills	481.98€ 459.03€	Buy
Kamagra Polo	100mg	20 Pills	83.56€ 79.58€	Buy
Viagra Generic	25mg	30 + 4 Pills	47.97€ 45.69€	Buy
Viagra Generic	50mg	90 + 6 Pills	107.37€ 102.26€	Buy
Kamagra	100mg	360 + 6 Pills	839.95€ 799.95€	Buy
Kamagra Soft Tabs	100mg	180 + 8 Pills	425.45€ 405.19€	Buy
Kamagra	100mg	12 Pills	55.64€ 52.99€	Buy
Viagra Generic	150mg	60 + 4 Pills	111.25€ 105.95€	Buy
Kamagra Polo	100mg	180 + 8 Pills	446.52€ 425.26€	Buy
Viagra Generic	150mg	90 + 6 Pills	147.18€ 140.17€	Buy
Kamagra Soft Tabs	100mg	12 Pills	57.55€ 54.81€	Buy
Viagra Generic	200mg	180 + 10 Pills	277.56€ 264.34€	Buy
Viagra Generic	200mg	270 + 10 Pills	379.76€ 361.68€	Buy
Kamagra Oral Jelly	100mg	220 + 18 Sachets	662.24€ 630.70€	Buy
Viagra Generic	25mg	20 Pills	37.74€ 35.94€	Buy

patient preference among various patient groups.

Vasodilator; Phosphodiesterase Type 5 Inhibitor compounded for dogs and cats.

This test was conducted in Kyukyu Pharmaceutical Co., Ltd, Toyama Plant, Japan. A thin pale red-colored ODF containing 50 mg sildenafil was formulated to dissolve in the oral cavity. Three batches of samples were subjected to a stability study at 60°C stress for three weeks. Subsequently, they were assessed for the amount of API assay (95.0%−105.0% of labeled amount), degradation, disintegration, dissolution rate (over 80% for 45 mm), and water content. All the test items of this stability study met the specifications and showed negligible differences between the samples.

Thermal Analysis and Solid-State Characterisation

The amount of degradation products demonstrated an increasing trend over time in all conditions, but all met the required specification. The purity testing for the degradation product (0.2% or less) showed significant results (p value < 0.05) at initial and 60°C in all the three samples. The process was evaluated across a range of manufacturing conditions, and all intermediates and sildenafil ODF showed reliable performance that yielded a consistent product meeting all specifications at release and after three weeks of storage under stressed conditions. These results, shown in , indicate the robust performance of the sildenafil ODF across a range of manufacturing conditions. In addition, the water content stayed in a tight range regardless of the film casting parameters, and this remains true of the packaged product even after 3 weeks at 60°C. Since each film or strip consists of precise

• Common side effects include headache, flushing, and dizziness.
• Allergic reactions are rare but require immediate medical attention.
• Effects usually last for 4 to 6 hours.

quantities of the APIs

13. Nonclinical Toxicology

The treatment strategies undoubtedly can reduce the initial symptoms and halt the progression of the disease. Some of the treatment approaches encompass psychosexological strategies, intraurethral or intracavernosal alprostadil self-injections, vacuum-assisted erection devices, low-intensity extracorporeal shock wave treatment, and penile implants. Nevertheless, after the efforts to modify unhealthy lifestyle and control risk factors and comorbidities, pharmacological management with oral PDE5-Is stays as the first-line treatment choice for ED because of its proven efficacy and better safety profile [Citation8]. The PDE5-Is inhibit the PDE5 enzyme concentrated in the smooth muscle cells in the blood vessels [Citation93]. Due to this inhibition, PDE5-Is prevent the enzyme-initiated degradation of cyclic guanosine monophosphate (cGMP), which causes elevation of cGMP in the vascular smooth muscle.

Surface Morphological Features and Particle-Size Distribution

Elevated cGMP levels lead to dilatation of the blood vessels due to phosphorylation of various downstream effector molecules, ensuring relaxation of smooth muscles [Citation94]. Inhibiting PDE5 produces a dilatation of the penile arteries that leads to a more prolonged and stable erection. Futhermore, PDE5-Is improve endothelial function and decrease apoptosis of smooth muscle cells in the corpus cavernosum [Citation93,Citation95]. Till date, the PDE5 inhibitors approved for the treatment of ED by the US Food and Drug Administration and European Union (EU) include sildenafil, tadalafil, vardenafil, and avanafil [Citation82,Citation96–98]. Sildenafil citrate, the first-in-class PDE5-I, is the most potent and selective inhibitor of cGMP-specific PDE5. and is devoid of physiological

6. Adverse Reactions/Side Effects

ED is defined as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance [Citation76,Citation79–81]. ED still prevails as an unprecedented diagnosis and undertreated condition that contributes to increased physical and psychosocial burden. It negatively impacts the wellbeing, relationships, and health-related quality of life (HR-QoL) of patients and their partners [Citation82,Citation83], and thus, any treatment interventions that substantially revive sexual function have the prospect to reinforce patient health and overall HR-QoL. ED may present with clinically relevant forms but also subclinical conditions deserving medical attention. Worldwide, various forms of ED are diagnosed in up to 150 million men and it has been projected to surge to 322 million cases by 2025.

Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately:

ED has affected 52% of men in the age group of 40 and 70 years and 70% of men above 70 years [Citation84–87]. The primary risk factors include diabetes mellitus, hypertension, and hyperlipidemia and modifiable risk factors like obesity, physical inactivity, alcoholism, and cigarette smoking [Citation88–90]. In addition, there is increasing evidence that ED can be considered as the perfect gender-dependent (early) biomarker of non-communicable diseases (NCDs) including peripheral vascular disease and cardiovascular disease, with a heightened risk of cardiovascular mortality as largely demonstrated by epidemiological studies [Citation91]. Indeed, ED can be considered a symptom for underlying NCD that may be explained as the classical canary in the coalmine [Citation92]. The management of ED includes the identification and control of risk factors and appropriate pharmacological and non-pharmacological therapy. variability in the gastrointestinal

Why trust our experts?

This study also identified the effect of food on the release pattern of drug and demonstrated the benefits of the administration of sildenafil ODT on empty stomach [Citation103]. examined and reported the bioequivalence of sildenafil citrate ODF and FCT with and without water in 2 randomized crossover studies [Citation75]. Owing to its unique pharmacological characteristics, quick disintegration within seconds, the novel sildenafil ODF is widely prescribed and preferred among ED patients. A study conducted in Japan surveyed 25 patients with ED regarding the ease of consumption and portability with the use of sildenafil ODF formulation. The survey items comprised (i) portability, (ii) storage techniques, (iii) ease of consumption, (iv) comfortableness, (v) extent of self-consciousness with their partner, (vi) thoughts on administering the film formulation, (vii) comparison with the tablets, and (viii) efficacy and adverse reaction.

5.4 Visual Loss

Of all the participants, 61.5% of the patients who switched from tablets to film quoted that storage and portability were improved and were comfortable during consumption. The study reported that most of their patients felt more at ease (69.2% who swapped from tablets to film and 75.0% belonged to the prescribed film-only category) and more comfortable with the film (61.5% who switched from tablets to film and 66.7% belonged to the prescribed film-only category). Mild hot flashes and headache were the only two adverse reactions with no severe adverse reaction reported by the study participants. The survey demonstrated improved ease of intake and portability with the orodispersible film compared to tablets [Citation104]. However, the efficacy of PDE5-Is has been thoroughly established, and the documented evidence reveals that a prominent proportion of patients discontinued this pharmacological therapy prematurely. tract, there is minimal

Author contributions

There is a gradual dissatisfaction noticed with the prescribed therapy among patients despite their successful intercourse. Studies depict that approximately 50% of men abandon their treatment with PDE5-Is in conventional formulations within a year [Citation105]. There is an immense need to understand individual patient’s needs and expectations regarding treatment for ED and also to comprehend their personal experiences and preferences. This will be instrumental in deciphering successful patient outcomes and satisfaction regarding the pharmacological therapy [Citation8]. ODFs were developed to overcome the above drawbacks of conventional oral solid dosing forms and to significantly improve patients’ compliance and acceptability to the pharmacological therapy. intersubject variability in clinical

5. Warnings and Precautions

ODFs are innovative and sophisticated drug delivery systems that disintegrate instantly in the mouth without the need for water. They unveil a prudent and easy mode of administration, with no risk of choking or inconvenience during swallowing. These attributes of ODFs improve compliance specifically in patients with dysphagia, and children and elderly population with comorbidities (e.g., renal impairment or congestive heart failure) when compared with conventional tablets or capsules. This noninvasive drug delivery system offers an altered clinical profile as it surpasses the enterohepatic circulation [Citation8]. Since the drug gets absorbed majorly from buccal mucosal tissues, it also reduces the risk of formation of toxic metabolites due to lowered hepatic metabolism [Citation106]. response unveiled by ODFs [Citation107].

Parameter	Value	Description	Notes
Absorption time	30-60 minutes	Time to reach peak plasma levels	Faster onset compared to tablets
Peak plasma concentration	150-200 ng/mL	Max systemic concentration	Varies per dose and individual
Half-life	4-5 hours	Time to reduce concentration by half	Helps determine dosing intervals
Bioavailability	40-50%	Fraction reaching systemic circulation	Slightly variable across patients